Servier announced a 16.2% year‑on‑year (YOY) revenue increase to EUR 6.9 billion (USD 7.52 billion) for the 2024/25 financial year, surpassing its EUR 6 billion target and reinforcing confidence in its 2030 strategic trajectory. Growth was led by strong oncology performance, particularly in the United States, while core products and expanded geographic reach supported broader momentum.
Financial Performance Summary
Metric
2024/25 Result
YOY Growth
Strategic Impact
Total Revenue
EUR 6.9 B (USD 7.52 B)
+16.2%
Exceeded EUR 6 B target
Oncology Revenue
EUR 2.21 B (USD 2.41 B)
+54.6%
32.2% of Group revenue
Cardiometabolism/Venous
EUR 2.97 B (USD 3.24 B)
+1.8%
Stable core portfolio
Brand‑Name Business
—
+18.1%
Key growth driver
Generics
—
+10.3%
Solid contribution
Key Product & Segment Drivers
Segment
Revenue
Growth
Key Drivers
Oncology
EUR 2.21 B
+54.6%
Voranigo (vorasidenib) US launch uptake
Cardiometabolism/Venous
EUR 2.97 B
+1.8%
Daflon and established brands
Geographic Strategy
—
—
US becomes largest unit, EU remains core
Geographic Performance Highlights
Region
Revenue
YOY Growth
% of Group Revenue
United States
EUR 1.496 B (USD 1.63 B)
+70.3%
21.8% (largest single unit)
European Union
—
+9.2%
40.5% (core market)
International Markets
—
Growing
Reflects diversification strategy
Strategic Implications & Outlook
Oncology Leadership: Voranigo’s strong US uptake validates Servier’s pivot toward high‑value oncology assets, positioning the company as a credible competitor in brain cancer therapy
US Market Transformation:70% revenue surge in the US reflects successful commercial infrastructure investment and regulatory execution
Portfolio Balance: While oncology drives headline growth, cardiometabolism/vascular franchise provides stable cash flow to fund R&D expansion
Geographic Diversification: International market growth reduces reliance on European reimbursement pressures
2030 Trajectory: Management expects oncology growth—especially in the US—to remain a key driver in the coming financial year, alongside stable core portfolio performance
Forward‑Looking Statements This brief contains forward‑looking statements regarding Servier’s revenue projections, market growth, and strategic execution toward 2030 goals. Actual results may differ due to competitive dynamics, regulatory changes, and market access challenges.-Fineline Info & Tech
By Fineline Cube 